Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Urology

• Publication date

  2009-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.urology.2008.08.476PMID 18950837PMCID PMC4723280
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Sorafenib in advanced clear-cell renal-cell carcinoma.

  2007cited by this paper
• Cancer Statistics, 2007

  2007cited by this paper
• Sunitinib in patients with metastatic renal cell carcinoma.

  2006cited by this paper
• Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence.

  2006cited by this paper
• Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma.

  2005cited by this paper
• Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma.

  2004cited by this paper
• Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells.

  2003cited by this paper
• A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

  2003cited by this paper
• Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial.

  2003cited by this paper
• Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial.

  2003cited by this paper
• Phase II trial of thalidomide for patients with advanced renal cell carcinoma.

  2002cited by this paper
• A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma

  2002cited by this paper
• A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.

  2001cited by this paper
• Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer

  2000cited by this paper
• Activity of thalidomide in AIDS-related Kaposi's sarcoma.

  2000cited by this paper
• Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization.

  1997cited by this paper
• Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid.

  1995cited by this paper
• Chemotherapy for advanced renal-cell carcinoma: 1983-1993.

  1995cited by this paper
• Thalidomide is an inhibitor of angiogenesis.

  1994cited by this paper
• Interim analysis: the alpha spending function approach.

  1994cited by this paper
• Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

  1991cited by this paper
• A randomized trial of postoperative radiotherapy versus observation in stage II and III renal adenocarcinoma. A study by the Copenhagen Renal Cancer Study Group.

  1987cited by this paper
• Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer: 5-year results of a prospective randomized study.

  1987cited by this paper

• Adjuvant treatment in intermediate/high-risk clear cell renal cell carcinoma. Systematic review.

  2025cites this paper
• Adjuvant Systemic Treatment for Renal Cancer After Surgery: A Network Meta-Analysis

  2022influential citation
• Instructions for Contributors

  2020cites this paper
• The adjuvant treatment of kidney cancer: a multidisciplinary outlook

  2019cites this paper
• Unified Approaches to Surgery and Systemic Therapy for Renal Cell Carcinoma

  2019cites this paper
• Evaluation of disease‐free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial‐level meta‐analysis

  2018influential citation
• Synergistic Inhibition of Thalidomide and Icotinib on Human Non-Small Cell Lung Carcinomas Through ERK and AKT Signaling

  2018cites this paper
• Adjuvant Therapies in Nonmetastatic Renal‐Cell Carcinoma: A Review of the Literature

  2018cites this paper
• Adjuvant therapy for locally advanced renal cell carcinoma: A meta-analysis and systematic review.

  2017cites this paper
• Positive Margins after Radical Nephrectomy with Venous Thrombectomy: Controversies and Treatment Options.

  2016cites this paper
• Renal cancer in adults

  2015influential citation
• Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents.

  2013cites this paper
• Adjuvant Systemic Therapy for Renal Cell Carcinoma

  2012cites this paper
• Adjuvant Therapy for Renal Cell Carcinoma

  2012cites this paper
• Neoadjuvant and adjuvant treatment of renal cell

  2012cites this paper
• Oncogenic CUL4A determines the response to thalidomide treatment in prostate cancer

  2012cites this paper
• Current Status of Targeted Therapy for Advanced Renal Cell Carcinoma

  2012cites this paper
• Systemic adjuvant therapies in renal cell carcinoma

  2012cites this paper
• Systemic therapy in renal cell carcinoma: advancing paradigms.

  2012cites this paper
• Neoadjuvant and adjuvant treatment of renal cell carcinoma

  2012cites this paper
• Integration of surgery and systemic therapy for renal cell carcinoma.

  2012cites this paper
• Adjuvant therapy for locally advanced renal cell cancer: A systematic review with meta-analysis

  2011influential citation
• Can a durable disease-free survival be achieved with surgical resection in patients with pathological node positive renal cell carcinoma?

  2011cites this paper
• Adjuvant and neoadjuvant therapies in high-risk renal cell carcinoma.

  2011cites this paper
• Update on targeted therapies for clear cell renal cell carcinoma

  2011cites this paper
• International consultation on urologic diseases and the European Association of Urology international consultation on locally advanced renal cell carcinoma.

  2011cites this paper
• Special Edition EAU-ICUD - Review - Kidney Cancer International Consultation on Urologic Diseases and the European Association of Urology International Consultation on Locally Advanced Renal Cell Carcinoma

  2011cites this paper
• Renal Neoplasia

  2011cites this paper
• Tratamiento de los tumores renales localmente avanzados

  2010cites this paper
• Recent updates in renal cell carcinoma

  2010cites this paper
• New systemic treatment options for metastatic renal‐cell carcinoma in the era of targeted therapies

  2010cites this paper
• Treatment of locally advanced renal tumors

  2010cites this paper
• Can vaccination or tyrosine kinase inhibitor therapy play a role in the adjuvant treatment of renal cell carcinoma?

  2010cites this paper
• Renal cell cancer: state of the art in adjuvant therapy.

  2010cites this paper
• [Treatment of locally advanced renal tumors].

  2010cites this paper
• Uro-Onkologie – Update 2009

  2009cites this paper
• Multimodality treatment paradigms for renal cell carcinoma: surgery versus targeted agents

  2009cites this paper
• Therapeutic advances in renal cell carcinoma

  year unknowncites this paper